Impact of clomiphene citrate during ovarian stimulation on the luteal phase after GnRH agonist trigger

REPRODUCTIVE BIOMEDICINE ONLINE

卷:28

Article

Derksen, L.¹  Tournaye, H.¹  Stoop, D.¹  Van Vaerenbergh, I.²  Bourgain, C.²  Polyzos, N. P.¹  Haentjens, P.^3,4  Blockeel, C.¹ 

[1] UZ Brussel, Ctr Reprod Med, B-1090 Brussels, Belgium

[2] Vrije Univ Brussel, Brussels, Belgium

[3] UZ Brussel, Ctr Outcomes Res, B-1090 Brussels, Belgium

[4] UZ Brussel, Expt Surg Lab, B-1090 Brussels, Belgium

关键词: clomiphene citrate;    GnRH agonist trigger;    GnRH antagonist;    ovarian stimulation;    recombinant FSH;    IVF/ICSI;   

DOI  :  10.1016/j.rbmo.2013.10.019

来源: Elsevier

【 摘 要 】

The use of a gonadotrophin-releasing hormone (GnRH) agonist to trigger final oocyte maturation in a GnRH antagonist protocol has been associated with poorer clinical outcomes due to an increased luteal-phase defect. It has been shown that LH activity is crucial in a normal luteal phase. Studies assessing the LH concentrations after clomiphene citrate co-treatment have observed increased luteal-phase LH concentrations. The purpose of this prospective cohort study was to analyse the effect of clomiphene citrate on the endocrine profile in the luteal phase when using GnRH agonist trigger. This was evaluated in eight oocyte donors undergoing ovarian stimulation using clomiphene citrate in combination with recombinant FSH compared with a control group of five donors treated with recombinant FSH only. The endocrine profile was comparable in both groups, except for serum LH concentrations on the day after trigger (121.3 +/- 53.0 IU/l versus 52.9 +/- 21.5 IU/l, respectively, P = 0.022). No significant differences in LH concentrations were found on the day of trigger or 5 days after oocyte retrieval. In conclusion, a luteal-phase defect was observed despite treatment with clomiphene citrate during ovarian stimulation. (C) 2013, Reproductive Healthcare Ltd. Published by Elsevier Ltd. All rights reserved.

【 授权许可】

Free